- Acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinsons disease.
Drug | Dosing Regimen | Dose Limit/ Maximum Dose | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
entacapone (ComtanR) | 200 mg PO with each dose of carbidopa/levodopa | 1600 mg/day | ||||||||||||||||
AzilectR (rasagiline) | 0.5-1 mg PO QD | 1 mg/day | ||||||||||||||||
selegiline (EldeprylR) | 5 mg PO BID | 10 mg/day | ||||||||||||||||
carbidopa/levodopa-extented release (SinemetR CR) | 25 mg/100 mg PO BID; 50 mg/200 mg PO BID | 12 tablets/day | ||||||||||||||||
carbidopa/levodopa-immediate release (SinemetR, ParcopaR) Dopaminergics | 10 mg/100 mg PO TID to QID; 25 mg/100 mg PO TID | carbidopa 200 mg/day | ||||||||||||||||
ropinirole (RequipR, Requip XLTM) | 0.25 mg PO TID titrate weekly to 3-9 mg PO TID | 24 mg/day | ||||||||||||||||
pramipexole (MirapexR) | 0.375 mg PO TID in divided doses increase every 5 to 7 days as needed. | 1.5 - 4.5 mg/ day | ||||||||||||||||
carbidopa, levodopa and entacapone (StalevoR) | Conversion of treatment regimen already stabilized on equivalent doses of carbidopa-levodopa and Comtan:
Conversion from tx without Comtan:
| 1600 mg/day (of entacapone) |
Drug | Dosing Regimen | Authorization Limit | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Apokyn | 0.2 ml SC initial test dose.
| HNCA: 6 months |